Prescribing Information for PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based. 

Paxlovid has a Conditional Marketing Authorisation in Great Britain. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.


Understanding the science behind PAXLOVID
A protease inhibitor that inhibits viral replication1,2
Explore more

See PAXLOVID in action


PAXLOVID's active pharmaceutical ingredient is nirmatrelvir, an oral protease inhibitor specifically designed by Pfizer to inhibit the main protease (Mpro), also known as 3-chymotrypsin-like cysteine (3CL) protease enzyme, and to help halt SARS-CoV-2 replication by preventing proteolysis from occurring.1,2

PAXLOVID also contains ritonavir, a CYP3A inhibitor that is widely used as a pharmacokinetic enhancer. Ritonavir is not active against SARS-CoV-2 3CL protease.1,2

How PAXLOVID works



1. Proteolysis 


In the SARS-CoV-2 life cycle, proteolysis involves the cleavage of viral polyprotein chains by proteases to release the nonstructural proteins that are essential for viral replication.3



2. Mpro


Due to its essential function, Mpro is unlikely to mutate, as any mutations are more likely to create a virus that is unlikely to survive.4



3. Nirmatrelvir 


Inhibition of Mpro by nirmatrelvir prevents proteolysis, helping to halt the viral replication cycle.1,2,4

EXPLORE MOREDosing

Learn about the oral treatment schedule, dose adjustments and drug interactions.

Dosing Information Loading Dose Adjustments Loading Drug Interactions Loading
References:
1.
PAXLOVID GB Summary of Product Characteristics. Pfizer Inc. 
2. PAXLOVID NI Summary of Product Characteristics. Pfizer Inc. 
3. Senger MR, Evangelista TCS, Dantas RF, et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz. 2020;115:e200254.
4. Goyal B, Goyal D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb Sci. 2020;22(6):297-305. 
PP-PAX-GBR-0592. February 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​